Table II.

Main characteristics of all studies included in this meta-analysis.

First author (ref)	Year	Location	No. of patients		Method	Cutoff	Stage	Chemotherapy	Survival analysis	Quality score
			High/Positive	Total
Baek (15)	2006	Korea	28	44	ICH	Percentage of cells stained 10%	Advanced	Cisplatin, 5-FU	Estimated	5
Kwon (22)	2007	Korea	45	64	ICH	Both staining intensity and percentage of cells stained ≥2	Advanced	Oxaliplatin, 5-FU	Multivariate	7
Wei (9)	2008	China	15	76	RT-PCR	Maximal χ2 method 0.47	III–IV	Oxaliplatin, 5-FU	Multivariate	7
Matsubara (10)	2008	Japan	36	139	RT-PCR	Maximal χ2 method 1.42×10−3	Advanced	Cisplatin, S-1	Univariate	7
Huang (19)	2008	China	31	62	RT-PCR	Median 0.672	I–IV	Oxaliplatin, 5-FU	Multivariate	7
Kim (20)	2009	Korea	86	153	ICH	Staining <17.5 vs. ≥17.5	III–IV	Cisplatin, 5-FU	Univariate	5
Bamias (16)	2010	Greece	46	66	ICH	Staining 0–1 vs. 2–6	I–IV	Cisplatin/carboplatin, docetaxel	Univariate	8
Ozkan (24)	2010	Turkey	13	41	ICH	Percentage of cells stained 10%	Advanced	Cisplatin, 5-FU	Estimated	6
Fareed (18)	2010	UK	19	57	ICH	Staining 0 vs. 1–3	I–IV	Cisplatin, 5-FU/Xeloda	Estimated	6
Kim (21)	2011	Korea	94	149	ICH	Both staining intensity and percentage of cells stained ≥2	II–IV	Cisplatin, 5-FU	Estimated	6
Squires (26)	2013	USA	16	73	ICH	Staining 0–2 vs. 3–4	I–III	5-FU, radiation	Multivariate	6
De Dosso (17)	2013	Switzerland	34	67	ICH	Staining 0–1 vs. 2–3	II–III	Cisplatin, 5-FU	Univariate	5
Yamada (8)	2013	Japan	160	322	RT-PCR	Median	Advanced	Cisplatin + irinotecan, 5-FU, S-1	Univariate	8
Liu (23)	2013	China	23	52	RT-PCR	Median 7.32	I–IV	Oxaliplatin/cisplatin	Multivariate	7
Qi (25)	2013	China	21	60	ICH	Median value of multiplying staining intensity by percentage of cells stained	Advanced	Oxaliplatin, 5-FU	Estimated	5

RT-PCR, reverse transcriptase polymerase chain reaction; IHC, immunohistochemistry; 5-FU, 5-fluorouracil; S-1, tegafur.